Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer

International Journal of Oncology

Volumn 13, Issue 6, 1998, Pages 1235-1240

  Murahashi, Kuniyasu ^a   Yashiro, Masakazu ^a   Inoue, Toru ^a   Nishimura, Shigehiko ^a   Matsuoka, Tasuku ^a   Sawada, Tetsuji ^a   Sowa, Michio ^b   Chung, Kosei Hirakawa Ys ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Osaka City General Medical Center   (Japan)

Author keywords

Cisplatin; Combination treatment; Fibroblasts; Growth inhibition; Scirrhous gastric carcinoma; Tranilast

Indexed keywords

CISPLATIN; TRANILAST;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT;

EID: 0031742140     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.6.1235     Document Type: Article

References (21)

1. Tahara E: Growth factors and oncogenes in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 116: 121-131, 1990.
2. Kitamura K, Beppu R, Anai H, Ikejiri K, Yakabe S, Sugimachi K and Saku M: Clinicopathologic study of patients with Borrmann type IV gastric carcinoma. J Surg Oncol 58: 112-117, 1995.
3. Maehara Y, Moriguchi S, Orita H, Kakeji T, Haraguchi M, Korenaga D and Sugimachi K: Lower survival rate for patients with carcinoma of stomach of Borrmann type IV after gastric resection. Surg Gynecol Obstet 175: 13-16, 1992.
4. Suga S, Iwase, H, Shimada M, Nishino Y, Ichihara T, Ichihara S, Kusugami K and Saito H: Neoadjuvant chemotherapy in scirrhous cancer of the stomach using uracil and tegafur and cisplatin. Internal Med 35: 930-936, 1996.
5. Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S, Kiyohashi A, Yaosaka T, Takahashi H, Ito T, Sasai T, Akiya T, Akazawa S, Betsuyaku T and Taguchi S: A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Jpn J Cancer Res 82: 613-620, 1991.
6. Chung YS, Yamashita Y, Inoue T, Matsuoka T, Nakata B, Onoda N, Maeda K, Sawada T, Kato T, Shirasaka T and Sowa M: Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma. Cancer 80: 1-7, 1997.
7. Loehrer PJ and Einhorn LH: Cisplatin. Ann Intern Med 100: 704-713, 1984.
8. Yashiro M, Chung YS and Sowa M: Role of orthotopic fibroblasts in the development of scirrhous gastric carcinoma. Jpn J Cancer Res 85: 883-886, 1994.
9. Suzawa H, Kikuchi S, Arai N and Koda A: The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol 60: 91-96, 1992.
10. Yashiro M, Chung YS and Sowa M: Tranilast (N-(3,4-dimethoxycinamoyl) anthranilic acid) down-regulates the growth-inhibition between gastric cancer cells and fibroblasts. Anticancer Res 17: 895-900, 1997.
11. Yashiro M, Chung YS, Nishimura S, Inoue T and Sowa M: Establishment of two new scirrhous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer 72: 1200-1210, 1995.
12. Kobayashi K, Kudoh S, Takemoto T, Hino M, Hayashihara K, Nakahiro K, Ando M and Niitani H: In vitro investigation of a combination of two drugs, cisplatin and carboplatin, as a function of the area under the c/t curve. J Cancer Res Clin Oncol 121: 715-720, 1995.
13. Goto Y, Tsuchiya O, Nishiyama M, Suzawa H and Miyata H: Studies on the metabolic fate of tranilast in rats and mice: pharmacokinetic studies in plasma, skin and granulation tissue. Clin Rep 25: 4767-4772, 1991.
14. Sun J, Qian Y, Hamilton AD and Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 55: 4243-4247, 1995.
15. Nagane M, Coufal F, Lin H, Bougleu O, Cavenee WK and Huang HJ: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-5086, 1996.
16. Yashiro M, Chung YS, Kubo T, Hato F and Sowa M: Differential response of scirrhous and well-differentiated gastric cancer cells to orthotopic fibroblasts. Br J Cancer 74: 1096-1103, 1996.
17. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, Inaguma Y, Taya K, Kawarada Y and Sakakura T: Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 84: 4621-4625, 1987.
18. Ankrapp DP and Bevan DR: Insulin-like growth factor-I and human lung fibroblast-derived insulin-like growth factor-I stimulate the proliferation of human lung carcinoma cells in vitro. Cancer Res 53: 3399-3404, 1993.
19. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J and Kerbel RS: Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 88: 6028-6032, 1991.
20. Gleave ME, Hsieh JT, Eschenbach AC and Chung LW: Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147: 1151-1159, 1992.
21. Okuda M, Ishikawa T, Saito Y, Shimizu T and Baba S: A clinical evaluation of N-5′ with perennial-type allergic rhinitis - a test by the multi-clinic, intergroup, double-blind comparative method. Ann Allergy Asthma Immunol 53: 178-185, 1984.